117 related articles for article (PubMed ID: 37708868)
1. Antibiotics May Interfere with Nivolumab Efficacy in Patients with Head and Neck Squamous Cell Carcinoma.
Ueta R; Imai H; Saijo K; Kawamura Y; Kodera S; Komine K; Ouchi K; Kasahara Y; Taniguchi S; Yoshida Y; Sasaki K; Shirota H; Takahashi M; Ishioka C
Oncology; 2024; 102(3):252-259. PubMed ID: 37708868
[TBL] [Abstract][Full Text] [Related]
2. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
Okamoto I; Sato H; Tsukahara K
Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271
[TBL] [Abstract][Full Text] [Related]
3. Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Wada A; Enokida T; Okano S; Sato M; Tanaka H; Ueda Y; Fujisawa T; Takeshita N; Tanaka N; Tahara M
Eur J Cancer; 2023 May; 184():30-38. PubMed ID: 36898232
[TBL] [Abstract][Full Text] [Related]
4. Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma.
Hori R; Shinohara S; Kojima T; Kagoshima H; Kitamura M; Tateya I; Tamaki H; Kumabe Y; Asato R; Harada H; Kitani Y; Tsujimura T; Honda K; Ichimaru K; Omori K
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31500103
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and/or a primary subsite excluded from CheckMate141, a retrospective study.
Ueda Y; Okano S; Enokida T; Fujisawa T; Ito K; Sato M; Tanaka H; Wada A; Tahara M
Oral Oncol; 2022 Jul; 130():105932. PubMed ID: 35636078
[TBL] [Abstract][Full Text] [Related]
7. Real-world 2-year long-term outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
Otsuki S; Hori R; Shinohara S; Kojima T; Tamaki H; Asato R; Kitamura M; Ichimaru K; Kitani Y; Kumabe Y; Honda K; Tsujimura T; Harada H; Ushiro K; Omori K
Auris Nasus Larynx; 2022 Oct; 49(5):834-844. PubMed ID: 35232636
[TBL] [Abstract][Full Text] [Related]
8. Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
Economopoulou P; Kotsantis I; Papaxoinis G; Gavrielatou N; Anastasiou M; Pantazopoulos A; Kavourakis G; Gkolfinopoulos S; Panayiotides I; Delides A; Psyrri A
Oral Oncol; 2020 Dec; 111():105013. PubMed ID: 32977184
[TBL] [Abstract][Full Text] [Related]
9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
10. Age-based efficacy and safety of nivolumab for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter retrospective study.
Kondo T; Okamoto I; Sato H; Koyama N; Fushimi C; Okada T; Masubuchi T; Miura K; Matsuki T; Yamashita T; Omura G; Takahashi H; Tsukahara K
Asia Pac J Clin Oncol; 2020 Dec; 16(6):340-347. PubMed ID: 32573033
[TBL] [Abstract][Full Text] [Related]
11. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
12. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of nivolumab as second line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a national DAHANCA cohort study.
Søby S; Gothelf A; Gyldenkerne N; Bentzen J; Nowicka-Matus K; Tramm T; Eriksen JG
Acta Oncol; 2022 Aug; 61(8):972-978. PubMed ID: 35913523
[TBL] [Abstract][Full Text] [Related]
14. Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival.
Lien MY; Wang TH; Hsieh CY; Tsai MH; Hua CH; Cheng FM; Chung WH; Tang CH; Chia-Hsun Hsieh J
Oral Oncol; 2021 Aug; 119():105380. PubMed ID: 34146822
[TBL] [Abstract][Full Text] [Related]
15. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
16. Real-World Experience of Immunotherapy from India in Recurrent Squamous Cell Carcinoma of Head and Neck Cancer.
Abbas W; Gupta S; Goel V; Rao RR; Pankaj P; Tripathi D; Patil PP; Popli S
South Asian J Cancer; 2021 Apr; 10(2):72-75. PubMed ID: 34568218
[No Abstract] [Full Text] [Related]
17. NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis.
Lurienne L; Cervesi J; Duhalde L; de Gunzburg J; Andremont A; Zalcman G; Buffet R; Bandinelli PA
J Thorac Oncol; 2020 Jul; 15(7):1147-1159. PubMed ID: 32173463
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma.
Okada T; Matsuki T; Fushimi C; Okamoto I; Sato H; Kondo T; Tokashiki K; Ito T; Masubuchi T; Tada Y; Miura K; Hanyu K; Omura GO; Takahashi H; Yamashita T; Oridate N; Tsukahara K
Anticancer Res; 2022 Oct; 42(10):4907-4912. PubMed ID: 36192003
[TBL] [Abstract][Full Text] [Related]
19. Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
Chung CH; Li J; Steuer CE; Bhateja P; Johnson M; Masannat J; Poole MI; Song F; Hernandez-Prera JC; Molina H; Wenig BM; Kumar S; Kuperwasser C; Stephens PJ; Farinhas JM; Shin DM; Kish JA; Muzaffar J; Kirtane K; Rocco JW; Schell MJ; Saba NF; Bonomi M
Clin Cancer Res; 2022 Jun; 28(11):2329-2338. PubMed ID: 35344035
[TBL] [Abstract][Full Text] [Related]
20. Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Guiard E; Clatot F; Even C; Perréard M; Abdeddaim C; Johnson A; Vauléon E; Rambeau A
Eur J Cancer; 2021 Dec; 159():125-132. PubMed ID: 34743067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]